This information is intended for U.S. Healthcare Professionals only.

Are you a U.S. Healthcare Professional?
No Yes

Gilteritinib (ASP2215) as Maintenance Therapy in FLT3/ITD+ Acute Myeloid Leukemia (AML) Patients in First Complete Remission

2215-CL-0302 / NCT02927262

A phase 3 double-blind, multicenter, randomized, placebo-controlled study of gilteritinib (ASP2215) as maintenance therapy following induction/consolidation therapy in AML patients with FLT3/ITD in first complete remission.

The safety and efficacy of the agent under investigation have not been established. There is no guarantee that the agent will receive regulatory approval and become commercially available for uses being investigated. All information current as of August 2017.

Now Enrolling
Pinch to zoom


Selection Criteriaa

• Morphologically confirmed AML in first complete remission

• Positive for FLT3/ITD mutation

• Patients who will not proceed with transplantation

• Patient is < 2 months from 1st day of last cycle of consolidation therapy

aNot a complete list of selection criteria.


Find out more at
Astellas Pharma
800-888-7704, ext 5473 A study of ASP2215 (gilteritinib), administered as maintenance therapy following indication/consolidation therapy for subjects with FMS-like tyrosine kinase 3 (FLT3/ITD) acute myeloid leukemia (AML) in first complete remission (06-26-2017). Accessed 07-27-2017.